Diagenode

Executive Summary

Diagenode is a privately held life sciences company headquartered in Liège, Belgium, founded in 2003. The company specializes in providing innovative solutions for epigenetics, chromatin analysis, and next-generation sequencing (NGS) sample preparation. Its product portfolio includes instruments, reagents, and services that empower research in epigenomics, DNA methylation, and proteomics, with a focus on advancing biomarker discovery and validation. With an estimated valuation of approximately $16.9 billion, Diagenode has established itself as a key player in the genomics and diagnostics space, serving academic and pharmaceutical customers globally. The company's comprehensive NGS sample preparation kits and epigenetic analysis tools are widely used in translational research and clinical development, positioning it to benefit from the growing demand for precision medicine and genomic data.

Upcoming Catalysts (preview)

• Q3 2026Launch of a novel NGS library preparation kit with enhanced sensitivity for liquid biopsy applications70% success
• Q4 2026Strategic partnership with a top-20 pharmaceutical company for epigenetics-based biomarker discovery in oncology50% success
• Q1 2027Release of a new high-throughput chromatin shearing instrument integrating automation for proteomics workflows60% success